Advances in massively parallel, next generation sequencing such as whole-exome sequencing (WES) have led to improved molecular diagnostic rates for rare and undiagnosed Mendelian disorders, identification of new pathogenic gene variants, better treatment options, and accurate prediction of recurrence risk.
1 WES in large cohorts of neurologic phenotypes including autism spectrum disorders, 2,3 intellectual disability, [4] [5] [6] and epilepsy 7, 8 have demonstrated a major contribution of rare, de novo variants to disease phenotypes. 9, 10 However, since many of these de novo variants are often seen in a singleton setting, it can be challenging to conclusively infer causality. Moreover, the extent to which the phenotype includes findings in addition to the developmental delay may not be initially appreciated. 11 This can be resolved by ascertaining a num-harbor the same recurrent de novo, potentially pathogenic variant, as seen in this series of seven individuals all with the same missense variant in the nucleus accumbens associated 1 gene (NACC1 [MIM: 610672] ). NACC1 is a member of the BTB/POZ domain-containing gene family and encodes for NAC1, a protein that functions as a transcriptional regulator. 12 Although NACC1 has not previously been associated with human Mendelian disease, its function makes it a plausible disease-associated gene, since it has been increasingly shown that a number of neurodevelopmental disorders are caused by misregulated gene expression. 13 The seven individuals we report here ( Figure 1 ) have a clinical constellation of severe to profound developmental delay and/or intellectual disability (HP: 0012736), epilepsy (HP: 0001250), feeding difficulties and/or feeding intolerance (HP: 0011968), irritability (HP: 0000737), and in the majority, postnatal microcephaly (HP: 0005484), bilateral cataracts (HP: 0000519), sleep disorder (HP: 0002360), and stereotypic motor behaviors (HP: 0000733). Detailed medical summaries and WES results are available in the Supplemental Data. Consent for publication was obtained from parents of all subjects, and procedures were followed in accordance with guidelines specified by Institutional Review Boards and Ethics Committees of each institution. Experienced pediatricians, geneticists, and neurologists clinically assessed the individuals.
The key clinical phenotypes are summarized in Table 1 . Most individuals had profound developmental impairment such that ambulation and speech were absent or greatly impaired. Infantile epilepsy had been noted in all seven individuals, with infantile spasms in four. Overall seizure control had been variable in the seven individuals but generally required multiple anti-epileptics and subspecialized neurologic care. Bilateral cataracts requiring surgical extraction were present in five out of seven (G-P) Axial T1 and T2 brain MRI images demonstrating mildly delayed myelination in individual 1 at 9 months old (G, L); severely delayed myelination and volume loss in individual 4 at 3 years old (H, M); severely delayed myelination and minimal volume loss in individual 5 at 10 years old (I, N); volume loss with normal myelination in individual 6 at 12 months old (J, O); and normal myelination and brain volume in individual 7 at 10 years old (K, P). The American Journal of Human Genetics 100, 1-9, February 2, 2017 3 individuals, with age of onset ranging from birth to 10 years, with variability in the type of cataracts. All individuals had a history of feeding difficulties or intolerance, with four out of seven requiring feeding by gastrostomy tube. Postnatal microcephaly was noted in five out of seven individuals, being evident prior to the onset of seizures in some individuals. All individuals were described as being irritable or having bouts of severe irritability. Hypotonia, sleep disorders, breath-holding spells, and repetitive or choreiform movements, hand flapping, or Rett-like hand automatisms were present in the majority of individuals. Interestingly, individuals presented here were consistently evaluated for severe infantile epilepsy disorders such as CDKL5 (MIM: 300203)-and ARX (MIM: 300382)-related diseases, in addition to MECP2 (MIM: 300005) and other Rett-like disorders due to the repetitive hand movements. Brain MR imaging showed delayed myelination in four individuals, decreased brain volume in six individuals, and focal cortical dysplasia in one individual (Figure 1 ). The appearance of a broad nasal tip was the only consistent facial dysmorphic feature noted in these individuals. Individuals 1, 2, 6, and 7 had trio exome sequencing, and individuals 3-5 had proband exome sequencing followed by Sanger confirmation (Figure 2 ). Detailed WES platform [14] [15] [16] and coverage for the seven individuals are listed in Table S1 . The WES data on individual 1 were reanalyzed after he was enrolled into the Undiagnosed Diseases Network (UDN (Figures 2A and 2B ). Sanger sequencing of this variant in all families confirmed de novo inheritance. Low alternative allele fraction observed in the exome data (93 reference allele and 20 alternate allele) and Sanger sequencing for individual 7 suggested NACC1 mosaicism. The significance of the allele balance bias observed at c.892C>T was evaluated by binomial test of the observed alternate allele counts and overall allele coverage of all well-covered (>103) heterozygous positions in the affected individual's exome. After adjusting p values using the Benjamini-Hochberg method with an FDR of 0.05, the NACC1 variant was confirmed mosaic (p < 0.0001). Parentage of six of the seven trio families was confirmed by trio exome sequencing (individuals 1, 2, 6, 7) or Sanger sequencing of rare variants (individuals 4 and 5) ( Table S2 ).
The c.892C>T transition occurs at a CpG dinucleotide within an arginine codon, a hypermutable CpG pattern reported in association with de novo events at numerous loci in the setting of advanced paternal age. [18] [19] [20] However, advanced paternal age was not a common feature of this cohort. Additional variants identified through exome sequencing in these individuals are summarized in Table S2 . The American Journal of Human Genetics 100, 1-9, February 2, 2017 5 residue is extremely conserved from human to zebrafish with a GERPþþ RS score of 4.89 ( Figure 3A ) and this variant is predicted to be deleterious by several prediction algorithms including align GVGD, PolyPhen, SIFT, and MutationTaster. These in silico analysis tools support the contention that the p.Arg298Trp change is likely to exert a specific functional effect on the protein.
Furthermore, we calculated the estimated probability of observing seven de novo NACC1 variants among the 17,228 individuals who underwent exome sequencing for neurodevelopmental/neurologic disorders across the different clinical testing laboratories and research studies that tested the seven individuals (GeneDx, 6,478; BHCMG, 3,400; Baylor, 6,250; UCLA, 1,100). The significance of this finding was evaluated using a binomial test, with the mutation rate as the probability of success, the number of individuals who underwent exome sequencing as the number of trials, and the number of probands who were found to have this mutation as the number of successes. 25 The probability of a chance occurrence is small and remains highly significant when Bonferonni correction is applied for the 3 billion base pairs in the genome (p ¼ 1.25 3 10 À14 ). Thus, our findings implicate NACC1
as a genome-wide significant disease-associated gene. Although NACC1 has not previously been associated with a Mendelian phenotype, a link between NACC1 and intellectual disability has been suggested, with apparent de novo variants being noted in single individuals within large sequencing studies of intellectual disability 5, 6 and autism spectrum disorder 2 cohorts (Table S3) . One female with intellectual disability (IQ of~45), autism, and schizo-affective disorder has been noted with a de novo missense allele c.1402C>T (p.Arg468Cys) in NACC1, located in a different region of the gene, the BEN domain ( Figure 3A ). 5, 6 In another exome-sequencing effort from the Simons Simplex Collection, one individual with autism spectrum disorder was identified to have a de novo splicing variant (presumably LoF), c.946þ2T>C, in NACC1. 2 These individuals do not appear to have, or at least were not reported as having, other key manifestations seen in our individuals, such as cataracts, epilepsy, irritability, and microcephaly. Contiguous gene deletions involving NACC1 are seen in 18 individuals in the DECIPHER database, ranging in size from 83 kb to 2.39 Mb, and duplications involving NACC1 are seen in 12 individuals, ranging in size from 211 kb to 58.83 Mb (Table S3) , and thus the relative contribution of the loss of NACC1 in these individuals is difficult to infer. A known microdeletion/microduplication syndrome involving chromosome 19p13.13 includes most of NACC1 along with~16 other genes and is characterized by macrocephaly, overgrowth, and intellectual disability, but it has been speculated that NFIX is the critical gene in the region. 26, 27 There are no copy losses involving NACC1 in non-disease individuals in the Database of Genomic Variants. 28 Taken together, none of the previous studies involving NACC1 aberrations report the syndromic phenotype we delineate here in the seven individuals carrying a de novo p.Arg298Trp variant, strengthening the phenotypic association specific to this missense change. Individual 7 had a milder clinical presentation compared to the other individuals reported here; at 12 years of age he had not developed cataracts, had normal tone and head size, and was ambulatory with limited speech. This may be explained by the likely mosaicism of the recurrent c.892C>T variant in peripheral blood, demonstrated by atypical allele balance ( Figures  2A and 2B ). Although the exact contribution of the mosaic NACC1 variant to the individual's milder phenotype is difficult to ascertain from exome data alone and requires further functional studies, previous studies suggest that mosaic mutations frequently occur in individuals diagnosed with intellectual disability and autism spectrum disorders. 29, 30 NAC1 has a documented role in cancer. NAC1 knockdown or overexpression of an NAC1 mutant containing only the BTB/POZ domain promotes cell apoptosis and senescence, inhibits cytokinesis, and prevents tumor formation. [31] [32] [33] NAC1 is upregulated in several types of neoplasms, especially ovarian serous carcinomas, either at the transcriptional level or through DNA amplification and overexpression. This is associated with cell proliferation, migration and invasion, chemotherapy resistance, tumor recurrence, and poor prognosis. 31, 32, [34] [35] [36] [37] While an oncogenic role has been proposed for NAC1's involvement in cancers, 32 we do not currently know whether or not our individuals with the recurrent p.Arg298Trp variant are at risk for cancers. Certainly, there is precedence for many genes in which germline variants cause neurodevelopmental disorders and somatic variants can be associated with cancers. [38] [39] [40] Previous studies have shown that NAC1 forms a homodimer or heterodimers with other binding partners through the BTB/POZ domain and functions as a transcriptional repressor through recruitment of histone deacetylase. 12, 41 The p.Arg298Trp variant is located outside the BTB/POZ domain that is important for cancer progression and the BEN domain in which one missense variant associated with intellectual disability has been reported 6 ( Figure 3B ). A dominant-negative function (especially since the protein dimerizes) or a gain-of-function (GoF) is possible for the p.Arg298Trp variant, since the prior reported LoF alleles in NACC1 result in an overlapping but less severe phenotype of intellectual disability and autism, 2, 6 and it is well known that LoF and GoF variants in the same gene can result in heterogeneous phenotypes with overlapping features. 25, 42, 43 Future studies are required to elucidate the mechanism of disease related to this NACC1 variant. NAC1 is known to have other biological functions, including involvement in psychomotor response to cocaine administration in rats, [30] [31] [32] vertebral patterning in mice, 44 interaction with Parkin suggestive of a role in
Parkinson disease, 45 and involvement with TDP-43, which is implicated in individuals with amyotrophic lateral sclerosis. 46 The role of NAC1 in normal neurologic function is highlighted by its role in mitigating protein turnover in dendritic cells and in maintaining synaptic plasticity. 40 As a transcriptional repressor and protein binding factor, NAC1 probably functions in regulating neural development and network establishment by altering expression, localization, and degradation of many downstream nervous system genes. Given the characteristic phenotype associated with the p.Arg298Trp variant, future transcriptional investigations may further delineate the impact of this rare, recurrent, highly penetrant allele and could potentially lead to targeted therapies. The constellation of cataracts, severe epilepsy, profound intellectual disability, irritability, microcephaly, and stereotypical movements is unusual and given the consistent occurrence of these phenotypes across our seven individuals, the allele-specific variant that we report in NACC1 should be considered strongly in individuals with similar features. Individual 2: A 12-year-old female presented to neurology clinic with epilepsy, microcephaly, cataracts, failure to thrive and severe developmental delay with regression. Her medical care had previously been managed in Saudi Arabia, so access to her full records was limited.
Supplemental Data
She was born at 36 weeks following induction of labor, but the reasons for this are unclear. By parental report she was small for gestational age and oligohydramnios was noted in the third trimester. She was admitted to the NICU for 7 days due to low weight and weakness.
The parents report normal development (she sat with support, rolled over) until 7-10 months of age when she began to lose motor skills, developed seizures, and was noted to be microcephalic.
She began having difficulty feeding, lost weight and was irritable with increased crying.
Currently all areas of development are profoundly impaired. She does not sit unsupported or speak. She does not have purposeful hand movement. She cries when she's hungry, and eats and drinks by mouth although there is concern with swallowing liquids.
She began having abnormal movements at 7 months of age which worsened by 10 months, described by parents as looking like seizures. At 11 months she was started on 3 AEDs during admission at a Saudi hospital, one of which was Clonazepam, but these records were unattainable. Her seizures have been managed solely with Clonazepam since 9 years old (duration of 3 years), although she continues to have seizures when doses of medication are missed. Seizures are described as paroxysmal quick jerk of arm upwards and head tilting to same side one time and then gradual relaxation. Seizures never last more than a few seconds, but can happen 100 times per day when off medications. She has never had a grand mal seizure. EEG at 12 years old showed only intermittent bifrontal slowing with no epileptiform discharges.
Her first cataract was diagnosed at 10 years of age, and the second at 11 years old. She has malformed globes. She has chronic anemia and also has had a reaction to sedation in the past that required CPR, intubation, and 1 week of ventilatory support.
On exam at 12 years of age, she was small with weight at 27.5 kg (<5 percentile), OFC at 46.5 cm (<2 nd percentile). She was mildly dysmorphic, had bilateral cataracts and was hypertonic when awake. She did not react to visual stimuli although was responsive to touch and sound. He was born at term via vaginal delivery to a 41-year-old G 3 P 2 mother and a 37-year-old father, both of Norwegian ancestry. His mother noted less movement during the pregnancy as compared to previous pregnancies. Birth weight was 4100 grams and birth length was 52 cm. Apgar score was 9. Hypotonia was noted at birth.
Developmental concerns were first noted at 8 weeks of age. He has had intensive psycho-motoric training, Domain patterning therapy from 14 months to 3 years of age, and Bobat neurodevelopmental training. Although he was able to stand with support during early childhood, he has never achieved ambulation. From age 14 he was unable to sit without support due to spasticity. He has no language but does make sounds and can express his likes and dislikes. He recognizes his parents and siblings but has had long-standing tactile aversion leading to strong dislike of being touched or held. This issue has gradually improved in adolescence.
First seizure activity was noted at 6 months and he has had a long-standing history of epilepsy.
Since 2 years of age he had tonic seizures. EEG at 5 ½ years of age showed increased activity, especially in the frontal lobe, related to his tonic-clonic seizures. Lamotrigine was initiated, which had no effect on the seizures and was discontinued after one year. Valproate therapy was effective, but EEG at 10 years of age still showed localized focal epileptic activity.
Bilateral congenital cataracts were diagnosed at 6 weeks of age, and he underwent surgery on the right eye at 1 year of age, and on the left eye at 2 years of age. He developed post-surgery cataracts and underwent laser surgery on the right lens at 2 years of age and left lens at 6 years of age.
MRI at 1 year of age showed reduced white matter and incomplete subcortical myelination of brain stem, thalamus and corpus callosum. MRI at 2 years of age showed increased myelination as compared to the first imaging although still somewhat reduced related to age, reduced white matter and a hypoplastic corpus callosum with temporal lobes most affected. MRI at 11 years of age showed increased subarachnoid fluid over the frontal cerebral convexities, over both lateral fossae and along the interhemispheric fissures, as well as hyperintense foci in both hippocampi consistent with hippocampal sulcus remnant and myelinated but thin corpus callosum. The findings indicated generalized atrophy and mildly decreased brain volume. MR spectroscopy was notable for lower NAA levels left central hemisphere.
Constipation and gastroesophageal reflux noted at 5 years of age. Due to low weight, reduced growth and feeding difficulties, percutaneous endoscopic gastrostomy was performed at 6 ½ years of age; however at 18 years of age he continues to eat oral meals every day. Due to spasticity he has developed contractures of the feet, knees and hips, which have been treated with orthopedic interventions including triple arthrodesis, bilateral adductor tendonectomy, and right side femur/pelvic osteotomy to correct hip subluxation and stabilize the hips. His knee contractures have been managed with repeated Botulinum injections. He has developed thoracolumbar scoliosis.
Since early infancy he has had bouts of inconsolability and screaming for days at a time.
Melatonin has been used for sleep disturbances. He has had Rett-like stereotypic hand movements since early childhood.
On exam at 6 ½ years of age he was microcephalic with OFC 49 cm (3 cm below 2.5 percentile).
He had hyperreflexic patellar tendons, normal Achilles tendon reflexes and downturned plantar reflexes. He had increased muscle tonus upper extremities. At 18 ½ years of age he had profound intellectual disability and stereotypic hand movements. He was born to a 30-year-old G 1 P 0 mother at 39 weeks gestation and weighed 7 pounds, 6 ounces.
The pregnancy was complicated by gestational diabetes at 28 weeks, requiring insulin at 36
weeks. Labor was induced at 39 weeks gestation for maternal hypertension. The delivery was uncomplicated.
He began exhibiting developmental delays and feeding difficulties within the first month of life.
Currently is able to roll over but cannot sit unassisted. He does not reach for or transfer toys.
Seizure activity was first observed at 4 months old; infantile spasms were diagnosed by EEG at 6 months and responded well to a 6 week course of ACTH. Levetiracetam was then initiated. He has been seizure free without AEDs since 2 years old (duration 17 months), and EEGs have been normal. He continues to have frequent sleep myoclonus.
Bilateral cataracts were diagnosed at birth and removed at 4 months of age. He has undergone bilateral goniotomy multiple times.
Brain MRI at 4 months showed mild delay in myelination and at 7 months showed significant interval cerebral volume loss. Brain imaging at 2 years, 2 months showed microcephaly and slight delay in myelination with considerable progression compared to previous imaging.
He has tracheomalacia, gastroesophageal reflux disease and feeding intolerance and disinterest which resulted in failure to thrive. Oral feeding improved during his ACTH treatment, however decreased significantly since completing therapy. Gastrostomy tube was placed at 9 months.
Mild hearing loss with normal tympanic membranes was found on ABR at 16 months.
He has periods of being irritable which last hours to days at a time where he has inconsolable crying. These are sometimes associated with constipation. He has sleep difficulties. He has a history of breath-holding spells which occurred several times a day prior to ACTH therapy; they seemed unrelated to seizures and cardiology evaluation was normal. The frequency of breathholding spells has decreased significantly, and they now occur only when he is upset.
On exam at 3 years, 7 months he had diffuse hypotonia. Previous testing included chromosome microarray and CDG. His mother also has congenital hearing impairment and left sided glaucoma secondary to an eye injury; remaining family history was noncontributory.
Individual 5: A 9-year-old Caucasian female had been followed since age 8 months by medical genetics for epilepsy, microcephaly, bilateral cataracts, failure to thrive and severe developmental delay. Prior to WES she had a diagnosis of mitochondrial disease based on muscle biopsy that showed a reduction in several respiratory chain complexes.
She was born via full-term normal spontaneous vaginal delivery to a 30-year-old G 1 P 0 mother and a 33-year-old father, with a birth weight of 7 pounds 10 ounces. The neonatal course was uncomplicated.
Early developmental milestones were normal (good head control, rolled at 2 months of age, pushed to a prone position at 2 to 3 months of age). She had a social smile and tracked visually at approximately 2 months, although she never made eye contact. Currently she is profoundly impaired with no speech, no visual tracking and limited purposeful movement.
Myoclonic seizures began at 5 months of age consisting of myotonic jerking of her upper extremities, and a diagnosis of infantile spasms was tentatively made. An EEG showed hypsarhythmia during sleep and overall was consistent with diffuse epileptic encephalopathy.
She was put on Zonisamide for presumed infantile spasms but continued to have clustering of seizures consisting of myotonic jerks as well as dozens of tonic jerks per day. At 10 months the Zonisamide was discontinued and her seizures doubled in frequency. Levetiracetam was started but discontinued after 2 weeks due to extreme irritability. Valproic acid was then initiated until an EEG at 11 months confirmed infantile spasms. ACTH was started at a low dose but spasms increased in intensity. Multiples AEDs were then attempted but did not result in improvement or had undesirable side effects, including Felbamate, Vigabatrin, Topamax, Lamotrigine and the ketogenic diet. Banzel (Rufinamide) was initiated at 2-½ years old, resulting in the first major improvement in her seizures. Seizures are currently well managed with Banzel, although there have been signs of breakthrough seizures with onset of puberty.
Nuclear cataracts were first noted in the right eye at 11 months and left eye at 12 months. She has had both cataracts as well as secondary cataracts removed during a total of four procedures.
A brain MRI at 5 months showed demyelination of the deep white matter. MR spectroscopy was normal.
She had feeding difficulties and formula intolerance requiring gastrostomy tube placement at 2-½ years of age, which was replaced 5 weeks later with a gastro-jejunal tube due to chronic vomiting. She has constipation and urine retention which has resulted in several UTIs. She has signs of precocious puberty since 5 years of age, and at 8 years of age hormonal changes were seen. She has had a single episode of difficulty waking up from anesthesia (following muscle biopsy at 2-½ years old).
She was a colicky baby and has had bouts of extreme irritability during childhood. At 2-½ years of age she began having choreic movements and increased sleep disturbance. Despite trials of Zolpidem, Lorazepam, Diazapam, Trazadone, Lortab, Gabapentin and Methadone, sleep patterns could not be stabilized. Around 5 years of age, an improvement was seen when calorie intake was lowered with a change to PurAmino formula, although she continues to have shorter bouts of extreme irritability. She has had breath-holding spells.
Previous diagnostic tests included a chromosome microarray, sequencing of the MECP2, CDKL5
and ARX genes, enzyme testing for Neuronal Ceroid Lipofuscinosis types 1 and 2, metabolic screens [plasma amino acids (very mild elevation of alanine), homocysteine, acylcarnitine profile, lactate, urine and plasma creatine studies, urine polyol studies (tenfold elevated ribitol), urine purine studies, urine organic acids (elevated lactate)]. CSF neurotransmitters and amino acids were normal. She had a muscle biopsy that showed a reduction in several respiratory chain complexes including complex 1 and complex 4, fulfilling minor criteria of the modified Walker criteria. Mitochondrial copy number was normal in the muscle sample and sequencing of the mitochondrial genome was likewise normal. She is the only child to her parents. Family history includes a paternal first cousin with seizures.
Individual 6: A 13-month-old male of Mexican ancestry was evaluated for developmental delay, hypotonia, infantile spasms, and bilateral sensory hearing loss.
He was born at 37 weeks gestation to a 31-year-old mother through induced vaginal birth after uneventful pregnancy and a 34-year-old father. The birth weight was 3.203 kg (30 th percentile) and length was 48 cm (20 th percentile). Slow heart rate was noted during birth.
Developmental concerns started at 4 months of age, when parents noticed that he would not laugh or look at them. At 6 months of age he failed a hearing and vision screen, and further evaluation identified bilateral sensorineural hearing loss and low vison, poor visual response, lack of tracking with both eyes, delayed visual maturation and bilateral hyperopia with astigmatism. At 9 months of age global developmental delay and hypotonia were noted. He began smiling and rolling over at this age. At 10 months old, breath holding spells with body stiffening was reported, followed by weakness. He had difficulty swallowing, and choked on thin liquids. He was not able to sit on his own, did not crawl, and had poor head control. Chromosomal microarray, creatine phosphokinase (CK), thyroid stimulating hormone (TSH) and acylcarnitine profile were normal. Family history includes a 33-year-old maternal aunt who has a seizure disorder with onset at age 15.
Individual 7: A 12-year-old male was evaluated for developmental delay, seizure disorder, and cortical dysplasia, with prior medical care managed in Columbia.
He was born at 40 weeks gestation via C-section for a cephalopelvic disproportion from a 29-year-old primigravida mother and a 32-year -old-father.
Developmental concerns were noted shortly after birth with poor suck. He had prolonged crying episodes with right arm posturing similar to dystonic posture. At three months persistent startle and lack of interaction were noted. At 6 months he was unable to roll over. 
Individual 6
No additional variant reported
Individual 7
Only heterozygous variants in known disease genes with autosomal dominant (AD) or X-linked (XL) inheritance and biallelic variants in known autosomal recessive (AR) disease genes are included here, and only for diseases where there is phenotypic overlap with the individuals' phenotypes. 
